Clinical Conversations®: Achieving Success in RA Assessment and Management

Program Overview

This activity features 2 patient cases, challenging interactive questions related to the cases, and video vignettes. You will have an opportunity to hear from our expert faculty and view practical examples of shared decision making.
Launch Date: February 27, 2018

Credit Expired

Target Audience

Rheumatologists – Relevant Terms: Rheumatoid Arthritis

Educational Objectives

Upon completion of this activity, participants should be better able to:

  • Discriminate between the effects of the tumor necrosis factor alpha (TNFα) and interleukin 6 (IL-6) signaling pathways in the pathophysiology of rheumatoid arthritis (RA) and provide a rationale for anti-cytokine therapy as a treatment approach
  • Incorporate validated and guideline-recommended disease activity monitoring to guide appropriate management for patients with RA
  • Develop individualized treatment plans for patients with RA that integrate new and emerging targeted and non-TNF disease modifying antirheumatic drugs (dMARDS) based on safety and efficacy data
  • Distinguish between TNF cycling and switching and prepare treatment plans that improve patient outcomes based on an understanding of the differences between the 2 options
  • Integrate shared decision making and other patient education strategies for patients with RA

Activity Faculty

Martin Jan Bergman, MD, FACR, FACP, FCPP

Martin Jan Bergman, MD, FACR, FACP, FCPP

Clinical Associate Professor, Medicine
Drexel University School of Medicine
Philadelphia, PA
Chief, Division of Rheumatology
Taylor Hospital
Ridley Park, PA

Sergio Schwartzman, MD

Sergio Schwartzman, MD

Franchellie M. Cadwell Associate Professor, Clinical Medicine
Weill Cornell Medical College
Associate Attending Physician
New York Presbyterian Hospital
Hospital for Special Surgery
New York, NY


Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources